Product Description
Mechanisms of Action: GLUN2A Antagonist,GLUN2C Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Austria | Belgium | Chile | Colombia | Egypt | France | Germany | Greece | Hungary | Ireland | Italy | Luxembourg | Netherlands | Norway | Peru | Portugal | Sweden | Switzerland | United Kingdom | United States | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|